Pharma — India Trademark Cases
454 decisions indexed
Page 13 of 16 · 454 total
Apex Laboratories Pvt. Ltd. v.Apex Formulations Pvt. Ltd.
The Madras High Court addressed an application seeking a stay in a trademark infringement suit. While the applicant argued for a stay pending opposition proceedings, the court determined that since the original suit was filed under the older Trade and Merchandise Marks Act, 1958, the relevant provisions applied. The court framed an issue questioning the validity of the plaintiff's trade mark registration and adjourned the case to allow the defendant time to comply with statutory requirements regarding challenging the trademark's validity.
Pfizer Products Inc & Anr v.Vijay Shah & Ors.
Pfizer successfully sued a competitor for trademark infringement and passing off regarding its popular cough syrup, COREX. The Delhi High Court granted permanent injunctions restraining the defendants from using the deceptively similar mark SOREX and associated packaging/labels. Furthermore, the court awarded punitive damages to Pfizer, reinforcing the legal protection afforded to registered trademarks in the pharmaceutical sector.
Glaxo Group Ltd. v.Sunlife Sciences Pvt. Ltd.
The Delhi High Court granted an ad interim injunction in favor of Glaxo Group Ltd. against Sunlife Sciences Pvt. Ltd. regarding trademark infringement. The court found that the defendant's use of deceptively similar names (B-NATE-C, CORSUN, ZEETAK) for pharmaceutical products was likely to cause consumer confusion with the plaintiffs' well-known brands (BETNOVATE, CROCIN, ZINETAC). Given the public interest in preventing the sale of spurious drugs, the court emphasized that prima facie evidence and balance of convenience favored restraining the defendant until the final trial.
Nne Pharmaplan India Ltd. v.M/S Cgmp Pharmaplan Pvt. Ltd. & Ors.
The Delhi High Court dismissed Nne Pharmaplan India Ltd.'s suit seeking permanent injunction against M/S Cgmp Pharmaplan Pvt. Ltd., which alleged passing off and infringement of its trade name 'PHARMAPLAN'. The court found that despite both companies operating in the pharmaceutical consulting sector, the names were sufficiently distinct ('NNE' vs. 'cGMP') to prevent customer confusion. Furthermore, the plaintiff failed to establish a prima facie case or irreparable loss, especially given their own inaction against other entities using similar terms.
Glaxo Group Ltd. v.Union Of India & Ors.
Glaxo Group Ltd. challenged the Intellectual Property Appellate Board's (IPAB) dismissal of its trademark registration appeal for 'VOLMAX.' The Delhi High Court intervened, finding that the IPAB had failed to properly consider key legal issues regarding deceptive similarity and the concept of a family of trademarks. Consequently, the High Court set aside the IPAB's order, restoring Glaxo's appeal to be decided afresh on all merits.
Modi Mundi Pharma Pvt. Ltd. v.Matrix Formulations & Anr.
The Delhi High Court ruled in favor of Modi Mundi Pharma Pvt. Ltd., finding that the defendant's use of 'NEUROCONTIN-800' infringed upon the plaintiff's registered trademark 'CONTIN'. The court held that the resemblance between the marks was likely to cause confusion and deceive consumers, thereby amounting to passing off. Consequently, the suit was decreed, granting permanent injunctions against the defendants and ordering them to surrender all infringing materials.
M/S Alkem Laboratories Ltd. v.Mega International (P) Ltd.
The Delhi High Court dismissed M/S Alkem Laboratories Ltd.'s appeal against a judgment that rejected its claim of passing off regarding the trademark 'GEMCAL'. The court found insufficient evidence to establish Alkem as the proprietor or prior user, noting that both parties were concurrent users. Furthermore, the court observed no instances of consumer confusion and noted significant differences in sales figures, concluding that Alkem's claims were unsubstantiated.
The Petitioner/Appellant (Name not specified) v.Cadilla Pharmaceuticals Ltd
The Madras High Court dismissed a petition seeking an interim injunction against Cadilla Pharmaceuticals Ltd, which was accused of infringing the petitioner's registered trademark CEFI-XL with its mark CEFOLAC-XL. The court found that there was no prima facie case of deception or confusing similarity between the two marks. Furthermore, the court noted the petitioner's delay in bringing the action (laches) and concluded that the balance of convenience favored the respondent, thus denying the temporary injunction.
Uas Pharmaceuticals Pty.Ltd. v.Ajantha Pharma Limited
The Madras High Court dismissed an appeal filed by Uas Pharmaceuticals, which sought an interim injunction against Ajantha Pharma regarding the use of the trade name 'SUNSTOP'. The court found that despite the appellant's international reputation, they had not established their mark in India. Crucially, the respondent was found to be first in the Indian market with a similar product, leading the court to uphold the denial of the injunction based on the balance of convenience and prima facie evidence.
M/S Bal Pharma Ltd. v.M/S Glenmark Pharmaceutical Ltd.
The Madras High Court dismissed a civil revision petition filed by M/S Bal Pharma Ltd against an order passed by the Intellectual Property Appellate Board (IPAB). The IPAB had granted a stay on the registration of a trade mark application, which was sought by Glenmark Pharmaceutical Ltd. The High Court found the IPAB's decision to be balanced and reasonable, noting that allowing immediate registration would create significant complications for the parties involved. Consequently, the court directed the IPAB to expedite the hearing and final disposal of the original appeal.
M/s.Orchid Chemicals & Pharmaceuticals Limited v.M/s.United Biotech Pvt. Ltd.
Orchid Chemicals filed appeals challenging the dismissal of its application for interim injunction against United Biotech, which was marketing a product under the mark 'FORZID' in Tamil Nadu. The court examined claims of trade mark infringement and passing off regarding the pharmaceutical preparation ORZID.
Sun Pharmaceuticals Industries Limited v.Cipla Limited
The Delhi High Court granted an interim injunction favoring Sun Pharmaceuticals against Cipla regarding the use of the trademark THEOBID-D. Despite arguments from the defendant citing statutory requirements for registered assignment, the court found that the plaintiff was entitled to protection based on prima facie rights and the potential irreparable injury caused by continued infringement in the pharmaceutical sector. The order restrained the defendant's associates from using the disputed mark during the pendency of the suit.
Macleods Pharmaceuticals Ltd. v.Alembic Limited
Macleods Pharmaceuticals Ltd. challenged an ex-parte injunction passed by the lower court against it, which restrained the use of its trade mark GEMIMAC due to alleged similarity with Alembic Limited's reputed trade mark GERIMAC. The appellant argued that the injunction was granted without issuing prior notice or recording adequate reasons, violating procedural requirements under the Code of Civil Procedure. The Gujarat High Court admitted the appeal and intervened, restricting the scope of the injunction until a proper hearing could take place.
Merck Kgaa v.The Registrar Of Trade Marks
Merck Kgaa appealed an order from the Assistant Registrar of Trade Marks regarding its trade mark 'CANDISTAT'. The core issue revolved around whether the appellant could be granted sufficient time to file necessary evidence in support of its opposition, despite procedural delays. The IPAB set aside the impugned order and allowed the appeal, emphasizing that opportunity must be granted to the applicant.
Amit R. Trivedi Trading As Active Health v.Assistant Registrar Of Trade Marks And ...
The appellant, a pharmaceutical manufacturer, appealed against the Assistant Registrar's refusal to register the trade mark SEREN. The appeal argued that since the product was a prescription drug, there was no likelihood of confusion. However, the IPAB found the marks (SEREN and SERENE) to be patently identical phonetically and structurally, concluding that the likelihood of deception was imminent.
Paras Pharmaceuticals Ltd. v.Ranbaxy Laboratories Ltd.
Paras Pharmaceuticals Ltd. filed a suit against Ranbaxy Laboratories Ltd., alleging that Ranbaxy was using negative advertisement and TV commercials for its pain reliever VOLINI to disparage Paras's popular product, MOOV. The court found that Ranbaxy's commercial depicted a box identical in artistic work and color scheme to MOOV, subtly suggesting that MOOV was inferior. Consequently, the Gujarat High Court allowed the appeal and directed Ranbaxy to change its packaging colors and cease using the appellant's artwork.
T.T.K.Pharma Limited v.Robapharam Ag
The appeal was filed by T.T.K.Pharma Limited against an order refusing to stay a suit filed by Robapharam Ag regarding the registered Trade Mark "OSSOPAN". The appellant argued that a rectification application under the Trade and Merchandise Marks Act, 1958, had been filed. However, the court dismissed the appeal, finding no merit in the request for a stay.
Reddy Pharmaceuticals Ltd. v.Dr. Reddy'S Laboratories Ltd.
The Delhi High Court dismissed an appeal, upholding the injunction granted against Dr. Reddy's Laboratories Ltd. The case centered on whether the defendant was passing off its products by using a deceptively similar name and logo ('Reddy') that accrued goodwill to the plaintiff's established trademark 'Dr. Reddy'. The court affirmed that while the defendant had initially been an agent, its subsequent entry into manufacturing finished dosage forms under the disputed brand constituted infringement. The judgment emphasized that even if alternative views were possible on the facts, appellate courts should not interfere with a trial court's properly exercised discretion. This ruling reinforces the importance of protecting established trade names and goodwill in the pharmaceutical sector.
Ranbaxy Laboratories Ltd. v.Pe-Mm Sp. Zo.O And Anr.
The Delhi High Court ruled in favor of Ranbaxy Laboratories Ltd. in its suit against Pe-Mm Sp. Zo.O regarding trademark infringement via domain name squatting. The court found that the defendant's registration of 'www.ranbaxy.eu' was unauthorized and deceptively similar to Ranbaxy's registered global trademark, 'RANBAXY'. Citing established principles, the judgment affirmed that a proprietor has a legitimate interest in protecting its brand identity across digital domains.
Apex Laboratories Private Limited v.K.Prasad Reddy
The Madras High Court allowed the petition filed by Apex Laboratories Private Limited seeking rectification and cancellation of a trademark registration granted to K.Prasad Reddy. The court found that the respondent's registration for 'ZINCOVIT' under Class 29 was mischievous and fraudulent, as the petitioner had been a prior user and proprietor of the mark since 1988/1990. Given the clear evidence of malafide intent and copying, the High Court ruled in favor of Apex Laboratories.
Ayurherbs Pharmaceuticals Private Limited v.Three-N-Products Private Limited
The Delhi High Court ruled in favor of Ayurherbs Pharmaceuticals, finding that Three-N-Products Private Limited was engaging in passing off by using the name 'Ayur' in its corporate identity. Despite arguments regarding product differences and derivation from Ayurveda, the court held that the use of the suffix 'Ayur Herbs Pharmaceuticals Private Limited' was likely to confuse the ordinary purchaser. This judgment reinforces the principle that trademark infringement can occur even if the goods are not identical, provided there is a likelihood of deception.
Sun Pharmaceutical Industries Limited v.Cipla Limited
The Bombay High Court rejected Sun Pharmaceutical Industries Limited's application for an interim injunction against Cipla Limited regarding the use of the trade mark 'Graniset'. Despite the similarity in marks and their use in treating nausea related to chemotherapy, the court found that the plaintiff lacked a prima facie proprietary right in the mark. The judgment highlighted the importance of prior user rights versus registration, while also noting the plaintiff's failure to provide supporting medical evidence for potential consumer confusion.
German Remedies Ltd. v.Commissioner Of Central Excise
German Remedies Ltd. challenged the Commissioner's decision regarding the classification and duty rate for its Acetyl Salicylic Acid (ASA) tablets. The dispute centered on whether the product, which was previously classified as a patent/proprietary medicament due to branding, should be treated as a generic product after dropping the trade mark. The Tribunal found that 'ASA' is merely an abbreviation of the chemical name and not a proprietary designation.
Dr. Anji Reddy (Appellant) v.Hoechst Aktiengesellschaft
The Madras High Court allowed an appeal filed by Hoechst Aktiengesellschaft against a single judge's decision, restoring the original trademark registration order. The dispute centered on whether the mark 'Novigan,' applied for in Class 5 (pharmaceutical preparations), was deceptively similar to the existing registered mark 'Novalgin.' The court found that despite structural similarities, the marks were phonetically and visually distinct enough not to cause confusion among the general public. This ruling emphasizes deference to technical authorities like the Assistant Registrar when assessing trademark similarity.
Dr. Anji Reddy v.Hoechst Aktiengesellschaft
This appeal concerned the registrability of the pharmaceutical trademark 'Novigan' against an objection raised by the owner of 'Novalgin'. The single judge had ruled that the marks were deceptively similar, but the Madras High Court overturned this decision. The court found no significant phonetic or visual similarity between the two marks, noting that common prefixes like 'Nova' are widely used in the pharmaceutical sector. Consequently, the original order allowing registration was restored.
Astrazeneca Uk Ltd. v.Orchid Chemicals And Pharmaceuticals
The Delhi High Court ruled in favor of the defendant, Orchid Chemicals, vacating an earlier interim injunction that had restrained them from using the trademark 'MEROMER'. The court found that while the plaintiff (Astrazeneca) claimed infringement based on deceptive similarity with 'MERONEM', the balance of convenience favored the defendant. Given that the defendant offered a cheaper alternative for the same essential drug, and considering other companies also used similar prefixes in the market, the court allowed the use of 'MEROMER' but mandated regular submission of sales accounts to safeguard the plaintiff's interests.
Cadila Healthcare Limited v.Lupin Laboratories Ltd.
This Gujarat High Court judgment addressed a critical jurisdictional dispute regarding trademark infringement suits. Cadila Healthcare challenged the jurisdiction of the Fast Track Court, arguing that Section 134 of the Trade Marks Act mandates such cases be heard only by a District Court. The Court ultimately rejected this contention, ruling that due to the structural provisions linking Fast Track Courts and Additional Judges to the District Judge's cadre, the Fast Track Court possesses the necessary jurisdiction to try the suit.
Glaxosmithkline Pharmaceuticals v.Theodar Laboratories Private Limited
The Delhi High Court ruled in favor of Glaxosmithkline Pharmaceuticals, granting a permanent injunction against Theodar Laboratories Private Limited for infringing on its trademarked product's packaging. The court found that the defendant's carton was a 'slavish imitation' of the plaintiff's distinctive color scheme and layout, which would mislead innocent consumers purchasing animal supplements. This judgment reinforces the protection afforded to trade dress in the pharmaceutical/feed supplement sector.
Pfizer Products Inc. v.Mr. Altamash Khan And Anr.
The Delhi High Court ruled in favor of Pfizer Products Inc., granting an interim order for the transfer of the domain name 'viagra.in' from the defendant to the plaintiff. The court recognized that a domain name is a valuable asset entitled to protection similar to a trademark, especially when it creates confusion or constitutes cyber squatting. This decision underscores the critical importance of securing digital real estate for major brands in the e-commerce era.
Allergan Inc. v.Chetana Pharmaceuticals
The plaintiff filed a suit for passing off against the defendant regarding the identical mark "Oxyline" used for medicinal products (eye drop vs. nasal drop). The court examined the claims of senior user status by both parties and the potential confusion arising from using similar marks on vital medicines.
Facing a trademark dispute?
Arctic's TM litigation team handles ~120 trademark matters per year across India, EU, and UK. From oppositions to infringement actions, we build winning arguments from precedent.